Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRM-151 in Myelofibrosis
NCT01981850Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2013
- Primary completion
- Jul 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 8
01
Overview
A Phase 2 trial of zinpentraxin alfa in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Roche. Started Oct 2013; status: completed.
02
Drugs
zinpentraxin alfa
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01981850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981850.